2023-04-17 11:02:23 ET
- Phio Pharmaceuticals ( NASDAQ: PHIO ) is trading ~11% higher after it said a preclinical study showed that intratumoral administration of its drug, mPH-762, stimulated a local anti-tumor immune response and generated systemic tumor-reactive memory T cells in mouse model.
- "These preclinical study results support intratumoral use of PH-762 in the clinical setting, with deeper understanding of the mechanism of abscopal efficacy," the company said.
- PH-762 is undergoing clinical development in a phase 1b trial for neoadjuvant treatment specifically designed for advanced resectable melanoma.
- Press Release
For further details see:
Phio Pharma rises 11% on positive data from preclinical study of PH-762 to treat melanoma